What Beriplast P Combi-Set Treats: Main Uses and Benefits

This therapeutic agent is applied in clinical settings that involve acute or unstable symptom patterns. It is considered relevant in contexts marked by increased discomfort or tension, supporting two main categories of conditions: hemostasis and tissue sealing.

The product is commonly used across conditions presenting with acute episodes where standard surgical techniques are insufficient to control bleeding, such as diffuse tissue bleeding, post-surgical fluid or air leakage, and symptoms related to systemic imbalance in high-risk patients. Fibrin sealants are used as supportive treatment for the improvement of hemostasis and for providing suture support.

The product is applied across domains where additional symptomatic support is needed to help address symptom clusters that may become intense or disruptive in complex surgery, including vascular, neurosurgical, and specialized abdominal procedures. This generally assists with maintaining functional stability and supports patients during difficult episodes by easing distress in contexts marked by increased discomfort.

---

Quick Fact: Support for Surgical Bleeding and Leakage Symptoms

• Focus: Managing symptoms related to physical discomfort and functional stress arising from active bleeding and structural vulnerability following complex surgical repairs.
• Benefit: Provides supportive assistance to control blood loss locally and helps maintain functional stability at the site of tissue repair.

Eligibility and Contraindications for Beriplast P Combi-Set

Official regulatory information defines specific populations that can and cannot use Beriplast P Combi-Set. The product is primarily established for use in Adult Patients (18 years and older) under standard labeled conditions.

Absolute Non-Eligibility (Contraindications)

Category	Restriction
Route of Administration	Must not be applied intravascularly (injected into an artery or vein) due to the risk of thromboembolism.
Sensitivity	Contraindicated in patients with a known hypersensitivity to any of the active substances (Human Fibrinogen, Human Thrombin, etc.) or excipients.
Bleeding Type	Must not be used for massive, high-pressure arterial or strong venous bleeding.

Restricted and Conditional Use

Category	Regulatory Status
Pediatric Use	Safety and efficacy have not yet been established in children and adolescents (under 18 years old).
Pregnancy/Lactation	Use is conditional; must be administered only if clearly indicated by a healthcare professional, as safety is not established in controlled trials.
Immune Status	Use requires special consideration in patients with immunodeficiency or conditions with increased erythropoiesis (e.g., hemolytic anaemia) due to potential viral risk from plasma-derived components.

Beriplast P Combi-Set Interactions with other medicines and products

The official regulatory prescribing information for Beriplast P Combi-Set establishes that the product's interaction profile is centered on local material incompatibilities rather than systemic drug interactions.

Due to its use as a localized biological sealant, no formal systemic drug-drug interaction studies have been performed to assess effects with co-administered oral or intravenous medicines.

Documented Local Interaction Restrictions

The most critical documented interaction relates to the potential for local deactivation of the product's active components, such as Thrombin, when exposed to specific substances. To prevent the denaturation (deactivation) of the product and ensure proper function, certain materials must be removed from the application site prior to use.

Substance Category	Required Action (Official Statement)
Alcohol	Must be removed from the application area
Iodine	Must be removed from the application area
Heavy Metals (e.g., in some antiseptics)	Must be removed from the application area

Furthermore, the regulatory labeling dictates strict preparation constraints. The product must not be mixed with any medicinal product or solvent other than the specific components provided within the Beriplast P Combi-Set kit for reconstitution.

Core Components and Target Interaction

Beriplast P Combi-Set delivers concentrated fibrinogen and thrombin to the application site. Thrombin functions as a serine protease enzyme, mediating the initial cleavage of fibrinogen into fibrin monomers. This enzymatic interaction is the central biological target that initiates the downstream cascade.

---

The Coagulation Cascade and Fibrin Formation

These fibrin monomers immediately self-assemble and rapidly polymerize through the spontaneous formation of intermolecular bonds, yielding a three-dimensional fibrin matrix. This polymerization reaction mimics and mediates the final stages of the natural coagulation cascade, resulting in the rapid formation of the insoluble fibrin structure.

---

Regulation and Degradation

Aprotinin is included in the solution to act as a protease inhibitor. This mechanism modulates the pathway by restricting the activity of the enzyme plasmin, thereby inhibiting fibrinolysis. The resulting fibrin matrix is eventually cleared from the local tissue through the normal physiological process of biodegradation over a period of time.

Administration Guidelines for Beriplast P Combi-Set

The following instructions detail the preparation and administration of Beriplast P Combi-Set.

---

Administration Scope

Entity	Official Instruction
Route of Administration	For epilesional use (local application to the tissue/wound surface only). Strictly NOT for intravascular application.
Dosing Schedule	The applied volume must be individualized by the treating physician, guided by the surgical procedure, the size of the area, and the intended application mode. Typical individual dosages have ranged from 0.5 ml to 4 ml, though larger volumes may be required for extensive procedures.
Frequency	Application can be repeated, if necessary, to achieve sufficient sealing. The kit is a single-use device intended for one patient during a single procedure.

---

Preparation and Procedural Steps

The product is supplied as two powders and two solvents, and must be reconstituted immediately prior to use with the devices provided in the kit. The reconstituted solutions must be inspected for particulate matter and used immediately after being drawn into the administration syringes.

1. Preparation of Site: The surface area of the wound must be dried by standard surgical techniques (e.g., compresses, suction) before applying the sealant.
2. Application: The two reconstituted solutions (Fibrinogen and Thrombin) are administered locally to the tissue, simultaneously or sequentially, using the specific application system (syringe holder and Y-piece) provided.
3. Completion: The fibrin sealant formation is typically complete after five to ten minutes at the latest.

---

Administration Rules

• Pediatric Use: Safety and efficacy in children and adolescents have not been established in controlled clinical studies.
• Procedural Constraint: Care must be taken to ensure the product does not enter the bloodstream to avoid life-threatening complications. Body parts outside the desired application area must be protected to prevent unintended tissue adhesion.
• Handling Restriction: Never push the syringe plungers against resistance as this indicates a blockage in the applicator, which must then be replaced.

Research evidence / Overview of studies for Beriplast P Combi-Set

Overview of the Research Landscape

The evidence base includes Randomized Controlled Trials (RCTs) and various multicenter clinical trials. These studies were designed to evaluate the product in research contexts involving fluctuating or unstable symptoms during surgical procedures. This research was studied for its application as a local adjunct, exploring how it was associated with certain surgical outcomes. The information summarized here is taken only from official regulatory and peer-reviewed scientific sources, contributing to the broader evidence landscape for fibrin sealants.

Evidence for Use in Achieving Local Hemostasis

The research explored the use of the product in surgical settings, including in situations involving diffuse tissue bleeding and bleeding associated with specific procedures like vascular graft repair. Short-term RCTs and prospective studies was studied for its use in outcomes related to systemic or functional imbalance, such as acute bleeding during operations.

The primary measures in these studies research examined objective outcomes like the duration required to reach a specific hemostasis endpoint and the quantification of blood loss. Findings describe patterns observed in the studies related to measured changes in the time to hemostasis within defined time intervals during the procedure. This research provides insight into short-term changes observed when the product was evaluated in adult patients undergoing these specific operations.

Evidence for Use in Tissue Sealing and Suture Support

The research exploring the product’s use for structural support includes Systematic Reviews and Meta-analyses that pooled data from multiple trials, alongside Observational Studies. These studies research explored the product's function in promoting adhesion and how it was associated with outcomes related to postoperative air or fluid leakage in conditions where symptoms may vary in intensity after surgery.

Studies monitored outcomes related to functional imbalance, such as the duration of postoperative drainage (for example, how long a chest tube was needed) and the incidence of prolonged air or fluid leakage (seroma or hematoma formation). In specific procedures, like certain lung surgeries, research describes patterns measured during the study period related to leakage. Findings were mixed when evaluating the use of the sealant for general fluid reduction across all surgical types, and evidence quality varies across studies due to differences in surgical techniques.

Long-term Studies and Follow-up Durations

Research in this area has explored the durability of the effect by observing patients over defined time intervals that extend beyond the initial hospital stay. Follow-up durations were limited for many studies focused on immediate hemostasis. However, some analyses related to tissue sealing, such as tracking recurrence after lung procedures, was associated with observations over intermediate and sometimes longer-term periods. Overall, the data are still emerging, and there is limited information for long-term outcomes regarding the maintenance of effect or the sustained structural integrity of the sealed site over multiple years.

Evidence in Special Populations

The research has predominantly included adult patients undergoing the studied procedures. For certain groups, such as pediatric and adolescent populations, data for certain groups remain insufficient. Research focusing on outcomes in adults was observed in some studies, but these specific young age groups may exhibit patterns different from those observed or have different outcomes. Therefore, controlled study data for these special populations are lacking, and research is ongoing.

What is Still Uncertain About Beriplast P Combi-Set Research

Evidence highlights what is known—and what is still uncertain—about the product’s use. Key research gaps include the need for more comparative evidence across a wider range of surgical and leakage scenarios. The inconsistency in findings and study heterogeneity across systematic reviews limit the ability to draw definitive, broad conclusions. Furthermore, the limited information for long-term outcomes and the insufficient data for pediatric and specific high-risk comorbidity groups mean that research does not determine whether an individual will respond similarly outside of the specific conditions under which the study results reflect. Comparative evidence is lacking for certain subgroups, and research is ongoing to address these known limitations.

Key Studies & References

1. Efficacy of Fibrin Sealant in Vascular Surgery: A Randomized, Controlled Trial

Common questions about Beriplast P Combi-Set (FAQ)

Q: Is Beriplast P Combi-Set considered a 'glue' or a 'sealant'?

Official documentation classifies Beriplast P Combi-Set as a Fibrin Sealant or a Topical Haemostatic Agent. It is engineered to mimic the final stages of the body's natural clotting process, creating a biological fibrin mesh to stop bleeding and promote tissue adhesion. Because of this function, it is sometimes used to describe its function as a tissue glue.

Q: Is Beriplast P Combi-Set derived from human plasma?

The key active components that form the biological seal—Fibrinogen and Thrombin—are derived from human plasma. The product contains components derived from human plasma and a bovine (cow) source for the protease inhibitor Aprotinin.

Q: What is the risk of getting a virus from a plasma-derived product like Beriplast P Combi-Set?

Since the product is made from human plasma, the risk of transmitting infectious agents, including unknown pathogens, cannot be entirely ruled out. Official documents state that the risk is addressed through mandated testing of all plasma donations and the use of specific viral inactivation and removal steps in the manufacturing process.

Q: How long does the fibrin clot from Beriplast P Combi-Set typically last?

The fibrin matrix that forms the sealant is temporary and designed to be broken down by the body’s normal physiological process of biodegradation. Studies and official documents indicate this breakdown and clearance occur over a period of time as the sealed area heals and is replaced by developing connective tissue.

Q: What happens if Beriplast P Combi-Set is applied in an area that is not fully dried?

Official product instructions mandate that the application site must be dried by standard surgical techniques before the sealant is applied. Applying the product to a wet surface may prevent the components from mixing correctly and potentially compromise the formation of the intended fibrin clot.

Q: What is the difference between a fibrin sealant like Beriplast P Combi-Set and a standard surgical stitch or suture?

Beriplast P Combi-Set is classified as a supportive treatment used as an adjunct to standard surgical techniques like stitches. While sutures are mechanical devices used to hold tissue together, the sealant creates a biological fibrin mesh, mimicking the body’s natural clotting mechanism to help stop bleeding and promote sealing.

Q: Is Beriplast P Combi-Set used for internal wounds or just on the surface?

The product is authorized for epilesional use, meaning it is applied locally to the tissue or wound surface. Regulatory documents confirm its use to assist with hemostasis and sealing during various surgical procedures, including those that involve internal tissues like vascular repair or liver operations.

Q: Can Beriplast P Combi-Set be used in the endoscopic treatment of gastrointestinal bleeding?

Yes. Official documentation confirms that Beriplast P Combi-Set is authorized for the supportive treatment of improving hemostasis, including use in the endoscopic treatment of bleeding gastroduodenal ulcers.

Q: What kind of severe adverse effects are mentioned in the product information?

Official regulatory documents list several severe adverse reactions. These include the potential for life-threatening allergic reactions, such as anaphylactic shock. It is also critically important that the product not be injected into a blood vessel (intravascularly), as this carries the severe risk of thromboembolic events (blood clots).

Q: What is the relevance of Parvovirus B19 to this type of medicine?

Official information mentions that the manufacturing steps used for plasma-derived products, while effective against many viruses, may have limited effectiveness against certain non-enveloped viruses, such as Parvovirus B19. Healthcare providers are advised to consider this information when using the product in patients who may be highly vulnerable to infection.

Q: Is Beriplast P Combi-Set the same as or similar to other fibrin sealants like Tisseel or Artiss?

Beriplast P Combi-Set belongs to the same class of drugs—fibrin sealants—used for similar purposes (hemostasis and sealing). However, regulatory analysis shows that products in this class can differ in their exact component concentrations, the specific viral inactivation methods used during manufacturing, and their handling characteristics.

Q: Is there clinical evidence supporting the use of Beriplast P Combi-Set in specific surgical fields?

Yes. Regulatory indications and clinical research specifically mention its use as an adjunct to hemostasis and sealing in surgical procedures. Examples of areas studied include vascular graft repair and support for sealing large tissue surfaces such as in liver surgery or for large burned surfaces.

Q: What is a fibrin sealant, and how is it different from general hemostatic agents?

A Fibrin Sealant is a specific type of Haemostatic Agent that works by supplying and activating the key clotting proteins, fibrinogen and thrombin, to form a biological fibrin clot. This is different from general hemostatic agents, not all of which function via this specific biological pathway.

Q: Are there any specific blood disorders that might make using Beriplast P Combi-Set more risky?

Regulatory documents state that special consideration is required for patients with certain immune status conditions, such as immunodeficiency or conditions involving increased red blood cell production (e.g., hemolytic anemia). This is due to the theoretical viral risk associated with all plasma-derived components.

Q: Can the application of Beriplast P Combi-Set be repeated if the initial application is not enough?

Official product labeling confirms that the application of the sealant can be repeated, if necessary, to achieve sufficient sealing or hemostasis during the procedure. However, the kit is a single-use device, meaning the kit itself is intended for use in one patient during a single procedure.

Q: Is the use of Beriplast P Combi-Set restricted to certain types of healthcare professionals?

The product is for professional surgical use only, as its preparation and administration require specialized training and equipment. The official volume and frequency of application must be determined and managed by the treating physician in the operating environment.

Q: Does Beriplast P Combi-Set come in different sizes or volumes?

Yes, regulatory listings show that the product is supplied in different kit volumes, such as 0.5 ml, 1 ml, and 3 ml. This allows healthcare providers to select the appropriate volume based on the size and complexity of the surgical need.

Q: How is Beriplast P Combi-Set metabolized or broken down by the body?

The formed fibrin matrix that constitutes the sealant is not permanent; it is metabolized and broken down by the body's natural process of biodegradation. As part of the wound healing process, the fibrin structure is gradually cleared and replaced by the body's developing connective tissue.

Q: What is Factor XIII's role in the sealant formed by Beriplast P Combi-Set?

The product contains Coagulation Factor XIII (FXIII). Its role is crucial: once the initial clot forms, activated FXIII functions as a fibrin-stabilizing factor. It strengthens the newly formed fibrin mesh by creating chemical cross-links, which increases the clot’s durability and resistance to premature dissolution.

Q: Do regulatory bodies specifically monitor the safety of fibrin sealants like this one?

Yes. As a product derived from human plasma, the safety of Beriplast P Combi-Set is subject to ongoing regulatory monitoring. Official guidance requires physicians to report any infections they suspect were transmitted by the product and mandates post-market surveillance for plasma-derived therapies.

Q: Why are there two different sets (Combi-Set 1 and Combi-Set 2) in the kit?

The product is intentionally supplied as two separate component solutions in the kit, which the name 'Combi-Set' refers to. The first component contains the fibrinogen, and the second contains the thrombin. This separation is necessary because the combination of these two components instantly triggers the formation of the sealant, meaning they can only be mixed immediately at the site of application.

Q: What does 'epilesional use' mean in the context of this medicine?

Official regulatory documents define the route of administration as epilesional use. This term means the product is applied locally to the tissue or wound surface only. It strictly means that the product must never be injected into a blood vessel (intravascularly).

Q: Does using Beriplast P Combi-Set typically shorten the overall operating time for certain procedures?

The research evidence base for the product has focused on measurable outcomes related to hemostasis. Studies examined the duration required to achieve hemostasis during surgery and describe observed patterns related to changes in this time frame in specific procedures. Regulatory documents do not make a blanket claim on shortening overall operating time.

Q: What are the risks of using Beriplast P Combi-Set via a spray application method?

Official warnings specify a severe risk of life-threatening or fatal air or gas embolism when using spray devices that employ a pressure regulator. When applying the product using a spray system, healthcare providers are strictly advised to follow instructions regarding pressure and distance to minimize this serious risk.

Q: Is there a risk of tissue damage when Beriplast P Combi-Set is used in the stomach or intestines?

Regulatory documents do not detail a specific risk of tissue damage in the stomach or intestines. Regulatory documents mention that care must be taken to prevent unintended tissue adhesion to body parts outside the desired application area.

Q: Are the manufacturing processes for Beriplast P Combi-Set designed to reduce the risk of viral transmission?

Yes. Regulatory documents confirm that the manufacturing process involves validated steps designed to reduce the risk of transmitting infectious agents. These steps include the screening of plasma donations and the use of viral inactivation methods, such as pasteurization.

Q: Does Beriplast P Combi-Set contain any animal-derived components?

Yes. The product contains Aprotinin, a protease inhibitor that is officially derived from a bovine (cow) source. This is used in the formulation to protect the formed seal from premature breakdown.

Storage and Disposal of Beriplast P Combi-Set

Beriplast P Combi-Set must be stored in a refrigerator at a strictly controlled temperature range of +2°C to +8°C. It is critical that the product must not be frozen. To ensure product integrity, the container must be stored in the outer carton for protection from light. The labeled shelf life for the unreconstituted product is 2 years under these conditions.

Once the product is reconstituted, regulatory documents mandate its use immediately from a microbiological safety standpoint. Although chemical stability is demonstrated for up to 24 hours at a maximum of +25°C, immediate use is required. For safety, the medicine must be stored out of the sight and reach of children.

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. The application set is designated as a single-use device and must not be reprocessed or reused.